Literature DB >> 19965833

Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation.

Takayuki Baba1, Mariko Kubota-Taniai, Masayasu Kitahashi, Kyoko Okada, Yoshinori Mitamura, Shuichi Yamamoto.   

Abstract

AIM: To compare the long-term outcome of photodynamic therapy (PDT) with that of intravitreal bevacizumab (IVB) for myopic choroidal neovascularizations (mCNVs).
METHODS: 24 eyes were selected from 40 consecutive patients with mCNV, and the patients were divided into Group A, consisting of 12 eyes treated by PDT, and Group B, consisting of 12 eyes treated by 1.25 mg IVB. The age and best-corrected visual acuity (BCVA) were matched between the two groups. The BCVA, size of the chorioretinal atrophy surrounding the CNV (CRA), central foveal thickness (CFT) and CNV thickness were determined before and at 12 and 24 months after the treatment.
RESULTS: The BCVA did not change after PDT but was significantly improved from 0.75+/-0.25 to 0.49+/-0.42 logMAR units at 12 months and to 0.50+/-0.38 logMAR units at 24 months after IVB. The CFT were significantly reduced in both groups at 12 and 24 months. The CRAs were larger in group A than in group B at 12 and 24 months, and their sizes were correlated with the BCVA.
CONCLUSION: At 24 months, IVB is more effective than PDT in treating mCNV. The enlargement of the CRA might be related to the incomplete visual recovery after PDT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965833     DOI: 10.1136/bjo.2009.166025

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  24 in total

1.  Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization.

Authors:  T Y Y Lai; F O J Luk; G K Y Lee; D S C Lam
Journal:  Eye (Lond)       Date:  2012-05-18       Impact factor: 3.775

2.  Comparison of foveal-sparing with foveal-involving photodynamic therapy for myopic choroidal neovascularization.

Authors:  C S Tan; M C Chew; T H Lim
Journal:  Eye (Lond)       Date:  2013-09-20       Impact factor: 3.775

3.  Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population.

Authors:  Leila El Matri; Fedra Kort; Ahmed Chebil; Rim Bouraoui; Ahlem Merdassi; Mejda Bouladi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-12       Impact factor: 3.117

4.  [Statement of the Deutsche Ophthalmologische Gesellschaft (German Ophthalmological Society), the Retinologische Gesellschaft (German Retina Society) and the Berufsverband der Augenärzte Deutschlands (German Professional Association of Ophthalmologists) on the therapy of choroidal neovascularization in myopia. State: March 2014].

Authors:  D Pauleikhoff; B Bertram; D Claessens
Journal:  Ophthalmologe       Date:  2014-03       Impact factor: 1.059

Review 5.  Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia.

Authors:  Ying Zhu; Ting Zhang; Gezhi Xu; Lijun Peng
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

6.  [Therapy of myopic choroidal neovascularization].

Authors:  B Voykov; F Ziemssen; K U Bartz-Schmidt
Journal:  Ophthalmologe       Date:  2012-08       Impact factor: 1.059

Review 7.  Recent trends in the management of maculopathy secondary to pathological myopia.

Authors:  D Mitry; H Zambarakji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-13       Impact factor: 3.117

8.  Combined photodynamic therapy and intravitreal bevacizumab as treatment for nonresponsive myopic choroidal neovascularization.

Authors:  Jay Kumar Chhablani
Journal:  Oman J Ophthalmol       Date:  2010-09

9.  Choroidal neovascularization following laser in situ keratomileusis for high myopia: a case series.

Authors:  Hui Yee Neo; Kumari Neelam; Chee Chew Yip; Hui Min Quah; Kah-Guan Au Eong
Journal:  Int Ophthalmol       Date:  2012-10-18       Impact factor: 2.031

Review 10.  Photodynamic therapy: current role in the treatment of chorioretinal conditions.

Authors:  D K Newman
Journal:  Eye (Lond)       Date:  2016-01-08       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.